PSA Healthcare: Olympus (7733 JT) – Time to Look Forward to FY24?
Asset sale gains by Olympus in FY22 made it hard for FY23 to look good anyway, but a procession of problems has turned a difficult situation into a bad one. However, with most of the issues being one-offs, a recovery in earnings is expected in FY24. With the shares down -30% from their peak, it may be time to revisit the stock.Olympus is a manufacturing company. Co. operates in four business segments. The Medical segment is engaged in the manufacture and sale of gastrointestinal endoscopes, surgical devices and peripheral devices for endoscopic surgery, endoscopic devices, and ultrasonic endoscopes. The Scientific Solutions segment is engaged in the manufacture and sale of biological microscopes, industrial microscopes and endoscopes, and non-destructive testing equipment. The Imaging segment is engaged in the manufacture and sale of digital cameras, IC recorders, and binoculars. The Others segment is engaged in the provision of bio-materials, system development and others.
Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods.
PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries.
The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.